Solvonis Therapeutics plc (LON:SVNS)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2120
-0.0180 (-7.83%)
Jun 4, 2026, 4:35 PM GMT
Market Cap15.65M +424.5%
Revenue (ttm)n/a
Net Income-5.74M
EPS-0.00
Shares Out 6.81B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume61,977,312
Open0.2200
Previous Close0.2300
Day's Range0.2120 - 0.2400
52-Week Range0.1300 - 0.4000
Beta1.19
Analystsn/a
Price Targetn/a
Earnings DateJun 12, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorde... [Read more]

Founded 2017
Employees 6
Stock Exchange London Stock Exchange
Ticker Symbol SVNS
Full Company Profile

Financial Performance

Financial Statements